Sponsor

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Clinical research sponsor

Published trials3
Recruiting shown2
Roles2
SourceClinicalTrials.gov

Clinical trials

3 shown
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.NCT07333066 · lead sponsor · 2026-06-05
RECRUITING
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate CancerNCT07717099 · lead sponsor · 2026-09-01
NOT_YET_RECRUITING
European Registry of Next Generation Imaging in Advanced Prostate CancerNCT06866782 · collaborator · 2024-09-17
RECRUITING

Sponsor roles

lead sponsor2
collaborator1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.